ArticlePloS one2026
A fusion-deletion genomic-event underlies poor prognosis in young patients with luminal breast cancer.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer in young patients, particularly those with the luminal subtype, exhibits more aggressive behavior and poorer clinical outcomes compared with older patients. However, the genomic mechanisms underlying this age-associated aggressiveness remains poorly understood. In this study, we integrated multi-omics data, including gene fusions, mutations, and copy number variations, to investigate age-related molecular heterogeneity in breast cancer. We identified the co-occurrence of the EEF1AKNMT::DNM3 (ED) fusion and KDM6B deletion as a novel prognostic biomarker associated with aggressive tumor biology and reduced survival in luminal breast cancer. Moreover, we discovered a widespread pattern of genomic remodeling in early-onset disease, characterized by an increased fusion burden, distinct mutational profiles, and dysregulated transcriptional programs that collectively contribute to high-risk clinical phenotypes. These findings provide mechanistic insights into the enhanced aggressiveness of breast cancer in young patients and identify potential biomarkers for improved risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.